The Effect on MRI of Gammaglobulin Treatment in Relapsing Multiple Sclerosis

Abstract

A number of uncontrolled studies and randomised, placebo-controlled trials have shown that treatment with intravenous gammaglobulin (NIG) reduces the exacerbation rate in relapsing multiple sclerosis (MS). Two randomised studies from Denmark and Israel, respectively have used MRI as efficacy endpoint In a Danish crossover trial, the number of gadolinium-enhancing lesions in serial cranial MRI was significantly reduced by approximately 60% during NIG treatment compared to placebo. Neither the Danish study nor an Israeli study were able to show significant reductions in the total lesion load on T₂-weighted cranial MRI. However, the studies were either too short or comprised too few patients for showing significant differences in T₂-weighted MRI. In conclusion, NIG is of benefit to patients with relapsing MS, but larger studies are required before the place of NIG in the treatment of MS can be established.

Keywords

intravenous immunoglobulin gammaglobulin G multiple sclerosis magnetic resonance imaging gadolinium-enhancing lesions clinical trials

Get full access to this article

View all access options for this article.

References

Sørensen

. (1996) Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. Multiple Sclerosis 1: 349–352.

Fazekas

(1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349: 589–593.

Sørenson

(1998) Intravonous immuglobin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50: 1273–1281.

Achiron

(1998) Intravonous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50: 398–402.

The IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43: 655–661.

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. (1995) Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 45: 1277–1285.

Jacobs

(1996) Intramuscular interferon bota-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neuro 39: 285–294.

PRISMS study group (Prevention of Relapses and Disability by Interferon bota-1a Subcutaneously in Multiple Sclerosis). (1998) Randomised doubel-blind placebocontrolled study of interferon-la in relapsing/remitting multiple sclerosis Lancet 352: 1498–1504.

Johnson

(1995) Copolymer 1 reduces relapse rate and improves disabilty in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268–1276.

10.

Johnson

(1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclorosis Study Group. Neurology 50: 701–708.

11.

The IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II. MRI analysis results of a multicentor, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43: 662–667.